New study to test anthrax drug in bioterror attack scenario

This study will evaluate how well the drug raxibacumab works and how safe it is for people who have symptoms of inhalational anthrax after a large-scale exposure, such as a bioterrorist attack. Up to 100 people of all ages, including pregnant women and children, who receive the drug from the national stockpile can take part. Researchers will collect data on survival and side effects, mostly by reviewing medical records after treatment.